John Alan Gray

John Alan Gray

Auto-generated profile, based on publicly available information

John Alan Gray

University of California, Davis

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2009 in Annual Review of Medicine
Verified
Journal Article
Closed access
MBMiles Berger
Miles Berger
JGJohn A. Gray
John A. Gray
BRBryan L. Roth
Bryan L. Roth
Serotonin is perhaps best known as a neurotransmitter that modulates neural activity and a wide range of neuropsychological processes, and drugs that target serotonin receptors are used widely in psychiatry and neurology. However, most serotonin is found outside the central nervous system, and virtually all of the 15 serotonin receptors are expressed outside as well as within the brain. Serotonin regulates numerous biological processes including cardiovascular function, bowel motility, ejaculatory latency, and bladder control. Additionally, new work suggests that serotonin may regulate some processes, including platelet aggregation, by receptor-independent, transglutaminase-dependent covalent linkage to cellular proteins. We review this new “expanded serotonin biology” and discuss how drugs targeting specific serotonin receptors are beginning to help treat a wide range of diseases.

1 June 2018 in Cell Reports
Verified
Journal Article
Open access
CLCalvin Ly
Calvin Ly
AGAlexandra C. Greb
Alexandra C. Greb
LCLindsay P. Cameron
Lindsay P. Cameron
JWJonathan M. Wong
Jonathan M. Wong
EBEden V. Barragan
Eden V. Barragan
DODavid E. Olson
David E. Olson
Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of depression and related disorders. The ability to promote both structural and functional plasticity in the PFC has been hypothesized to underlie the fast-acting antidepressant properties of the dissociative anesthetic ketamine. Here, we report that, like ketamine, serotonergic psychedelics are capable of robustly increasing neuritogenesis and/or spinogenesis both in vitro and in vivo. These changes in neuronal structure are accompanied by increased synapse number and function, as measured by fluorescence microscopy and electrophysiology. The structural changes induced by psychedelics appear to result from stimulation of the TrkB, mTOR, and 5-HT2A signaling pathways and could possibly explain the clinical effectiveness of these compounds. Our results underscore the therapeutic potential of psychedelics and, importantly, identify several lead scaffolds for medicinal chemistry efforts focused on developing plasticity-promoting compounds as safe, effective, and fast-acting treatments for depression and related disorders.

17 February 2023 in Science
Verified
Journal Article
Closed access
MVMaxemiliano V. Vargas
Maxemiliano V. Vargas
LDLee E. Dunlap
Lee E. Dunlap
CDChunyang Dong
Chunyang Dong
SCSamuel J. Carter
Samuel J. Carter
RTRobert J. Tombari
Robert J. Tombari
DODavid E. Olson
David E. Olson
Decreased dendritic spine density in the cortex is a hallmark of several neuropsychiatric diseases, and the ability to promote cortical neuron growth has been hypothesized to underlie the rapid and sustained therapeutic effects of psychedelics. Activation of 5-hydroxytryptamine (serotonin) 2A receptors (5-HT2ARs) is essential for psychedelic-induced cortical plasticity, but it is currently unclear why some 5-HT2AR agonists promote neuroplasticity, whereas others do not. We used molecular and genetic tools to demonstrate that intracellular 5-HT2ARs mediate the plasticity-promoting properties of psychedelics; these results explain why serotonin does not engage similar plasticity mechanisms. This work emphasizes the role of location bias in 5-HT2AR signaling, identifies intracellular 5-HT2ARs as a therapeutic target, and raises the intriguing possibility that serotonin might not be the endogenous ligand for intracellular 5-HT2ARs in the cortex.

1 October 2010 in Neuron
Verified
Journal Article
Closed access
NJNarinobu Juge
Narinobu Juge
JGJohn A. Gray
John A. Gray
HOHiroshi Omote
Hiroshi Omote
TMTakaaki Miyaji
Takaaki Miyaji
TITsuyoshi Inoue
Tsuyoshi Inoue
YMYoshinori Moriyama
Yoshinori Moriyama

1 September 2011 in Neuron
Verified
Journal Article
Closed access
JGJohn A. Gray
John A. Gray
YSYun Shi
Yun Shi
HUHiroshi Usui
Hiroshi Usui
MDMatthew J. During
Matthew J. During
KSKenji Sakimura
Kenji Sakimura
RNRoger A. Nicoll
Roger A. Nicoll

1 November 2001 in Brain Research Bulletin
Verified
Journal Article
Closed access
JGJohn A Gray
John A Gray
BRBryan L Roth
Bryan L Roth